Navidea taps Goldman as prez, CEO
Navidea (NYSE:NAVB) appointed Dr. Michael Goldberg as president & CEO in late September this year. The Dublin, Ohio-based company’s board of directors also promoted board member Eric Rowinsky to chairman of its board of directors, a role previously held by Dr. Goldberg.
Dr. Goldberg, who has been a member of the board of directors since 2013, served as interim CEO from May – October 2014. He has held a senior executive position at Emisphere Technologies, Inc. and VP of investing banking at First Boston Corporation, where he helped found the Healthcare Banking Group.
“We are delighted to announce the appointment of Michael as Navidea’s CEO,” Rowinsky said in prepared remarks. “Dr. Goldberg is a visionary leader with a deep knowledge and appreciation for the potential of Navidea’s macrophage targeting technology platform and its wide range of diagnostic and therapeutic applications. At this important transition point for the company, we will benefit greatly from his expertise as we drive the development of our Manocept clinical immunodiagnostic and immunotherapeutic programs to deliver targeted products to improve patient outcomes.”
“I look forward to spearheading the growth of both Navidea and Macrophage Therapeutics as we execute our mission to not only diagnose but treat disease,” Dr. Goldberg added. “The combination of exceptional technology, a strong leadership team as well as our expectation of improved financial stability will allow us to effectively execute on our strategy to more rapidly advance on numerous development programs with our ground-breaking proprietary technology for multiple high value indications.”